Apixaban

被引：8

作者：

Bates, S. M. ^{[1
]}

Weitz, J. I. ^{[1
,2
]}

机构：

[1] McMaster Univ, Dept Med, Hamilton, ON, Canada

[2] McMaster Univ, Dept Biochem, Hamilton, ON, Canada

来源：

DRUGS OF THE FUTURE | 2008年 / 33卷 / 04期

关键词：

factor Xa inhibitor; anticoagulant;

D O I：

10.1358/dof.2008.033.04.1187022

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Currently available anticoagulants include heparin, low-molecular-weight heparin, fondaparinux and warfarin. Despite advances, currently available agents have limitations that have provided the impetus for the development of new drugs for the prevention and treatment of both venous and arterial thromboembolism. Novel anticoagulants targeting specific steps in coagulation are in various stages of development. Apixaban (BMS-562247) is an orally available, highly selective, reversible inhibitor of factor Xa that is currently in late-stage clinical development. Preclinical and phase I studies showed that this agent is safe, well tolerated and has antithrombotic activity. Promising phase II studies evaluating apixaban for the prevention and treatment of venous thromboembolism have been completed and phase III clinical studies are ongoing.

引用

页码：293 / 301

页数：9

共 59 条

[1] Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery [J].